skip to content »

Pathology & Immunology

Houston, Texas

Pathology and Immunology
Pathology & Immunology
not shown on screen

Shu Feng, M.D., Ph.D.

Assistant Professor

Education

Ph.D. - Cell Biology, China Medical University, Shenyang, China

M.D. - Jiamusi College of Medicine, Jiamusi, China

M.S. - Pharmacology, China Medical University, Shenyang, China

Post-Doctoral Training

Baylor College of Medicine, Houston, Texas

Institute of Biosciences and Technology, Texas A&M University, Houston, Texas

Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang, China

Current Position

Assistant Professor, Department of Pathology & Immunology, Baylor College of Medicine, Houston Texas

Professional Positions Held

Assistant Professor, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas (2011-present)

Instructor, Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas (2009-2011)

Intructor, Department of Obstretrics and Gynecology, Baylor College of Medicine, Houston, Texas (2007-2009)

Professor, Director, Department of Microbial Engineering, Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang, China (1998-2001)

Membership on Professional Organizations

America Association of Cancer Research

Representative Publications

  • Feng S, Dakhova O, Creighton C and Ittmann M. 2013. Role of the endocrine fibroblast growth factor FGF19 in prostate cancer. Cancer Res. 73(8):2551-62.
  • Feng S, Shao L, Yu W, Gavine P and Ittmann M. 2012. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. Clin Cancer Res, 18(14):3880-88.
  • Feng S, Agoulnik AI. 2011. Expression of LDL-A moduleof relaxin receptor in prostate cancer cells inhibits tumorigenesis. Int J Oncol, 39(6):1559-65.
  • Yu W, Feng S(Co-first author), Dakhova O, Creighton CJ, Cai Y, Li R, Frolov A, Ayala G, Ittmann A. 2011. FGFR-4 Ar enhances prostate cancer progression via mitogen activated protein kinase and serum response factor signaling. Clin Cancer Res, 17(13):4355-66.
  • Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya E, Pereira R, Kaur S, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. 2010. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer, 17(4):1021-33
  • Feng S, Agoulnik IU, Li Z, Hand HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. 2009. Relaxin/RXFP1 signaling in prostate cancer progression. Ann NY Acad Sci, 1160:379-80.
  • Feng S, Ferlin A, Truong A, Bathgata R, Wade J, Corbett S, Han S, Tannour-Louet M, Lamb D, Foresta C, Agoulnik A. 2009. INSL3/RXFP2 signaling in testicular descent: mice and men. Ann NY Acad Sci, 1160:197-204.
  • Ferlin A, Pepe A, Gianesello L, Garolla A, Fang S, Giannini S, Zaccolo M, Facciolli A, Morello R, Agoulnik AI, Foresta C. 2008. Mutations in the insulin-like factor 3 receptor are associated with osteoporosis. J Bone Miner Res. 23(5):683-693.
  • Feng S, Agoulnik UI, Bogatcheva NV, Kamar AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. 2007. Relaxin promotes prostate cancer progression. Clin. Cancer Res, 13(6):1695-1702.
  • Feng S, Bogatcheva NV, Troung A, Korchin B, Cishop CE, Klonisch T, Agoulnik IU, Agoulnik AI. 2007. Developmental expression and gene regulation of insulin-like3 receptor Lgr8 in male reproductive organs. Biol Reprod, 77(4):671-680.
  • Agoulnik AI, Feng S. The Genetics of Cryptorchidism.pp185-198, In: The Genetics of Male Infertility. Edited by:D.T. Carrel. Humana Press Inc., Totowa, NJ 2007.
  • Feng S, Bogatcheva VN, Kamat AA, Truong A, Agoulnik IA. 2006. Endocrine effects of transgenic relaxin in mice. Endocrinology, 147(1):407-414.
  • Feng S, Bogatcheva VN, Truong A, Engel W, Adaham IM, Agoulnik AI. 2006. Overexpression of Insulin- like 3 dose not rescue cryptorchidism in Gnrhr or Hoxa10 deficient mice. J Urology, 176(1):399-404.
  • Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Sood AK, Agoulnik AI. 2006. The Role of Relaxin in Endometrial Cancer. Cancer Biology & Therapy, 5(1):71-77.
  • Feng S, Bogatcheva VN, Kamat AA, Agoulnik AI. 2005. Genetic targeting of relaxin and Insl3 signaling in mice. Ann NY Acad Sci, 1041:82-90.
  • Humtsoe JO, Bowling RA Jr, Feng S, Wary K. 2005. Murine lipid phosphate phosophohydrolase-3 acts as a cell-associated integrin ligand. Biochem Biophys Res Commun, 335(3):906-1009.
  • Feng S, Cortessis VK, Hwang A, Hardy B, Koh CJ, Bogatcheva NV, Agoulnik AI. 2004. Mutation analysis of INSL3 and GREAT/LGR8 genes in familial cryptochidism. Urology, 64(5):1032-36.
  • Kamat AA, Feng S, Bogatcheva NA, Truong A, Bishop CE, Agoulnik AI. 2004. Genetic targeting of relaxin receptor and Insulin-like factor 3 receptors in mice. Endocrinology, 145:4712-20.
  • Bogatcheva NV, Trough A, Feng S, Engel W, Adham IM, Agoulnik AI. 2003. GREAT/LGR8 is the only receptor for insulin-like 3 peptide. Mol Endocrinol, 17(12):2639-46.
  • Humtsoe JO, Feng S(Co-first author), Thakker GD, Yang J, Hong J, Wary KK. 2003. Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP. The EMBO J, 22(7):1539-54.

E-mail this page to a friend